In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall SA

www.almirall.es

Latest From Almirall SA

GW Pharmaceuticals Scores EU First For Cannabinoid Drug

GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.

Europe Approvals

Pent-Up Demand As GW Pharma’s Epidyolex Approved In Europe

Drug will meet pent-up demand in Europe for clinically proven cannabis-based medicine for hard-to-treat epilepsy.

Europe Approvals

InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis

A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.

 

Gastrointestinal Clinical Trials

Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.

Dermatology Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Almirall Prodesfarma SA
  • Laboratorios Almirall SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • Almirall SA
  • Senior Management
  • Eduardo Sanchiz Yrazu, CEO
    Jorge Gallardo Ballart, Pres.
  • Contact Info
  • Almirall SA
    Phone: (34) 93 291 30 00
    Ronda General Mitre, 151
    Barcelona, 08022
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register